Voriconazole

Contraindicated

Voriconazole Colchicine Colcrys Explained Increased colchicine exposure and an increased risk of fatal toxicity Details Voriconazole Simvastatin Flolipid Explained Increased simvastatin exposure, an increased risk of simvastatin adverse effects an increased risk of rhabdomyolysis, increased vo... Details Voriconazole Dihydroergotamine Injection DHE-45® Injection Increased ergot derivative exposure and an increased risk of ergotism (nausea, vomiting, vasospastic ischemia) Details Voriconazole Dihydroergotamine Nasal Spray Migranal Increased ergot derivative exposure and an increased risk of ergotism (nausea, vomiting, vasospastic ischemia) Details Voriconazole Finerenone Kerendia Increased finerenone exposure and an increased risk of finerenone-related adverse effects Details Voriconazole Ivabradine Corlanor Increased ivabradine exposure, an increased risk of ivabradine-related adverse effects and an increased risk of QT prolongation Details Voriconazole Ketoconazole Topical Extina® Foam Increased risk of QT interval prolongation, an increased ketoconazole exposure, an increased risk of ketoconazole-related adverse... Details Voriconazole Lovastatin Altocor® Increased plasma levels of lovastatin and an increased risk of myopathy or rhabdomyolysis Details Voriconazole Lurasidone Latuda Increased lurasidone exposure and an increased voriconazole exposure Details Voriconazole Methylergonovine Methergine Increased ergot derivative exposure and an increased risk of ergotism (nausea, vomiting, vasospastic ischemia) Details Voriconazole Naloxegol Movantik Increased naloxegol exposure and an increased risk of naloxegol-related adverse effects Details Voriconazole Nimodipine Nimotop Increased niMODipine exposure Details

Major

Voriconazole Acetaminophen And Codeine Capital® & Codeine Explained Increased codeine and morphine exposure Details Voriconazole Clindamycin ANTIROBE Explained Increased CYP3A4 substrates exposure and an increased efficacy of CYP3A4 substrates-related adverse effects Details Voriconazole Omeprazole Gastrobim Explained Increased omeprazole exposure an increased voriconazole exposure Details Voriconazole Amitriptyline Elavil Explained An increased risk of QT interval prolongation Details Voriconazole Sertraline Explained An increased risk of QT interval prolongation, an increased sertraline exposure and an increased risk of sertraline-related advers... Details Voriconazole Buprenorphine Belbuca Explained An increased risk of QT interval prolongation, increased buprenorphine exposure and an increased risk of buprenorphine-related adv... Details Voriconazole Relugolix Orgovyx Explained Increased risk of QT interval prolongation, reduced voriconazole exposure and an reduced efficacy of voriconazole Details Voriconazole Abrocitinib Cibinqo Explained Increased abrocitinib exposure, an increased risk of abrocitinib-related adverse effects, an increased voriconazole exposure and a... Details Voriconazole Acalabrutinib Calquence Increased acalabrutinib exposure Details Voriconazole Ado-Trastuzumab Emtansine Injection KADCYLA Increased exposure of cytotoxic component DM1 (maytansine derivative) and risk of toxicity Details Voriconazole Alpelisib Piqray Increased CYP3A4 substrates exposure and an increased efficacy of CYP3A4 substrates-related adverse effects Details Voriconazole Amisulpride Injection Barhemsys Increased risk of serious ventricular arrhythmias such as torsades de pointes Details Voriconazole Apixaban Eliquis Explained Increased apixaban exposure and an increased efficacy of apixaban-related adverse effects Details Voriconazole Arsenic Trioxide Trisenox An increased risk of QT interval prolongation Details Voriconazole Aripiprazole Injection Abilify Increased ARIPiprazole exposure and an increased risk of QT interval prolongation Details Voriconazole Arsenic Trioxide Injection Trisenox An increased risk of QT interval prolongation Details Voriconazole Asciminib Scemblix Increased asciminib exposure, an increased risk of asciminib-related adverse effects, an increased voriconazole exposure and an in... Details Voriconazole Asenapine Transdermal Patch Secuado An increased risk of QT interval prolongation Details Voriconazole Atogepant Qulipta Increased atogepant exposure Details Voriconazole Avapritinib Ayvakit Increased avapritinib exposure and increased incidence and severity of adverse reactions Details Voriconazole Avatrombopag Doptelet Increased CYP3A4/CYP2C9 substrate exposure and an increased of CYP3A4/CYP2C9 substrates-related adverse effects Details Voriconazole Azathioprine Azasan An increased risk of hepatotoxicity Details Voriconazole Azithromycin AzaSite An increased risk of QT interval prolongation, an increased voriconazole exposure and an increased risk of voriconazole-related ad... Details Voriconazole Belumosudil Rezurock Explained Increased CYP3A4 substrate exposure, an increased CYP3A4 substrate-related adverse reactions, an increased voriconazole exposure a... Details Voriconazole Bicalutamide Casodex Increased voriconazole exposure and an increased risk of voriconazole-related adverse reaction Details Voriconazole Atorvastatin Atorvaliq Increased atorvastatin exposure, an increased risk of myopathy, an increased voriconazole exposure and an increased risk of vorico... Details Voriconazole Cariprazine Vraylar Explained Increased exposure to cariprazine and its active metabolite, didesmethylcariprazine Details Voriconazole Abiraterone Abirtega Increased CYP3A4 substrates exposure and an increased efficacy of CYP3A4 substrates-related adverse effects Details